Syndax Pharmaceuticals, Inc.
$17.62
Market Cap
$1.57B
Shares Outstanding
89.3M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Mar 3, 2016
Round Lot
100
Locale
US
Day Open
$17.64
Day High
$17.95
Day Low
$17.37
Volume
5.18M
VWAP
$17.61
Prev Close
$17.68
Transactions
--
Acc. Volume
--
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.
Syndax Pharmaceuticals, Inc. (SNDX) closed the 2026-09-18 session at $17.62, down 0.34% versus the previous close (-0.06). The stock opened at $17.64 and traded between $17.37 and $17.95 during that session. Session trading volume was 5.2M shares. The volume-weighted average price (VWAP) is $17.61.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.
Syndax Pharmaceuticals, Inc. has a market capitalization of $1.57 billion. The company operates in the PHARMACEUTICAL PREPARATIONS industry classification. SNDX is listed on the XNAS exchange. The company employs approximately 298 people. Syndax Pharmaceuticals, Inc. is headquartered in NEW YORK, NY. The recorded listing date is 2016-03-03.
On this page you can find market SNDX stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the PHARMACEUTICAL PREPARATIONS sector.